Faculty of Medicine, Riga Stradiņš University, LV-1007 Riga, Latvia.
Faculty of Residency, Riga Stradiņš University, LV-1007 Riga, Latvia.
Medicina (Kaunas). 2024 Aug 20;60(8):1352. doi: 10.3390/medicina60081352.
: COVID-19 disease, caused by the SARS-CoV-2 virus, has presented significant challenges to global health, with acute and chronic implications for various aspects of well-being, including sleep and quality of life. This study aimed to investigate the impact of SARS-CoV-2 infection on sleep quality, daytime sleepiness, and quality of life in hospitalised and home-treated patients after three and six months. : A longitudinal cohort study was conducted, enrolling hospitalised patients from a single clinical university hospital and home-treated participants through a survey spread through social networks. Individuals who had tested positive for the SARS-CoV-2 virus in the past three months and had a symptomatic course of the disease were included in the study. Participants with previously diagnosed sleep disorders were excluded from the study. Participants were evaluated using internationally validated self-evaluation scales, including the Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9 (PHQ-9) and Fatigue Severity Scale (FSS). Data were collected three and six months after laboratory-confirmed SARS-CoV-2 infection, with informed consent obtained from all participants. Statistical analysis was performed using the Wilcoxon signed rank test, Fisher-Freeman-Halton exact, Pearson Chi tests and Spearman correlation. Results were considered statistically significant with value < 0.05. : In total, 66 participants with a mean age of 44.05 ± 21.61 years were enrolled in the study. Most patients ( = 36) were treated at home and 30 at hospital. Six months after SARS-CoV-2 infection, home-treated patients reported a higher prevalence of poor sleep quality (52.8%, = 19, = 0.015, PSQI) and hospitalised patients showed a lower prevalence of depressive symptoms ( < 0.001, PHQ-9) as 90% ( = 27) had minimal or no symptoms compared to 30.6% ( = 11) in a home-treated group. These findings mark the importance of the COVID-19 patients' management settings as people treated at home had worse sleep quality and more depressive symptoms six months after infection indicating worse life quality.
新型冠状病毒（SARS-CoV-2）引起的 COVID-19 疾病对全球健康构成了重大挑战，对幸福感的各个方面都有急性和慢性影响，包括睡眠和生活质量。本研究旨在调查 SARS-CoV-2 感染对住院和居家治疗患者三个月和六个月后睡眠质量、日间嗜睡和生活质量的影响。
本研究采用纵向队列研究，从一家临床大学医院招募住院患者，并通过社交网络传播的调查招募居家治疗的参与者。纳入过去三个月内 SARS-CoV-2 检测呈阳性且有症状性疾病病程的患者。患有先前诊断的睡眠障碍的患者被排除在研究之外。使用国际上经过验证的自我评估量表评估参与者，包括 Epworth 嗜睡量表（ESS）、匹兹堡睡眠质量指数（PSQI）、患者健康问卷-9（PHQ-9）和疲劳严重程度量表（FSS）。在实验室确认 SARS-CoV-2 感染后三个月和六个月收集数据，所有参与者均获得知情同意。使用 Wilcoxon 符号秩检验、Fisher-Freeman-Halton 精确检验、Pearson Chi 检验和 Spearman 相关分析进行统计分析。 结果以 值 < 0.05 为具有统计学意义。
共有 66 名平均年龄为 44.05 ± 21.61 岁的患者入组本研究。大多数患者（= 36）在家中接受治疗，30 人在医院接受治疗。SARS-CoV-2 感染后六个月，居家治疗患者报告睡眠质量较差的比例较高（52.8%，= 19，= 0.015，PSQI），住院患者报告抑郁症状较轻的比例较低（< 0.001，PHQ-9），90%（= 27）无或几乎无症状，而居家治疗组中这一比例为 30.6%（= 11）。这些发现标志着 COVID-19 患者管理环境的重要性，因为在家中接受治疗的患者在感染后六个月睡眠质量较差，抑郁症状较多，表明生活质量较差。
